CURE’s breast cancer page is an extensive resource of cancer information featuring the latest breast cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on breast cancer.
May 2nd 2025
New results from a breast cancer-related lymphedema study show the importance of measuring fluid and body composition before treatment begins.
Progression of HER2+ Metastatic Breast Cancer
March 30th 2021Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, shares the hope she had after progression because of the ongoing research for HER2+ breast cancer, and Sara A. Hurvitz, M.D., reviews the drug regimens available in this realm.
‘The Future is Brighter’ for Triple-Negative Breast Cancer
March 11th 2021Triple-negative breast cancer, which is found in 15%-20% of invasive breast cancers, is a challenge when it comes to treatment, but thanks to new drug approvals and therapy regimens, the treatment landscape has progressed in recent years, according to an expert.
How Targeted Therapies Are Changing the Breast Cancer Treatment Landscape
March 11th 2021Targeted therapies that attack cancer in a more precise way than traditional chemotherapy are being used more often in the field of breast cancer, but the solution in utilizing them lies within the patient-oncologist relationship, according to an expert from the Massachusetts General Hospital Cancer Center.
‘Lost in Transition’ After Breast Cancer
March 9th 2021With more than 4 million breast cancer survivors in the U.S., survivorship care and understanding what happens to patients after surviving is of the utmost importance. An expert explains some side effects survivors may experience and treatments to help.
FDA Rejects Approval of Oral Paclitaxel Plus Encequidar for Metastatic Breast Cancer: Here’s Why
March 5th 2021Last week, the Food and Drug Administration (FDA) was scheduled to make a decision on whether or not they would approve oral paclitaxel plus encequidar for the treatment of metastatic breast cancer. The agency decided not to approve the regimen, and issued a complete response letter outlining why.